The Warren Alpert Foundation Prize is awarded annually to scientist(s) whose scientific achievements have led to the prevention, cure or treatment of human diseases or disorders, and/or whose research constitutes a seminal scientific finding that holds great promise of ultimately changing our understanding of or ability to treat disease. The prize was established in 1987 by the late philanthropist and businessman Warren Alpert [1] and the Warren Alpert Foundation.
The Warren Alpert Prize is given internationally and since its inception, 10 winners have gone on to win Nobel Prizes. [2]
The prize is administered in concert with Harvard Medical School in Boston, Massachusetts and the Warren Alpert Foundation, located in Providence, Rhode Island. An annual symposium is held at Harvard Medical School each fall where the recipient(s) present their work. The prize currently includes $500,000, [3] a citation and plaque.
Year | Recipient(s) | Citation | Nationality |
---|---|---|---|
2023 | David J. Lipman | For his visionary work in the conception, design, and implementation of computational tools, databases, and infrastructure that transformed the way biological information is analyzed and accessed freely and rapidly around the world. | United States |
2022 | Katalin Karikó, Drew Weissman, Eric Huang, Uğur Şahin, Özlem Türeci | For transformational discoveries into the biology of mRNA, for its modification for medicinal use, and for the design of mRNA-based COVID-19 vaccines. | United States |
2021 | Lynne Maquat, Joan Steitz | For the discovery of fundamental pathways and mechanisms that ensure accurate RNA splicing and quality control of gene expression involving RNA. [4] | United States |
2020 | Daniel Drucker, Joel Habener, Jens Juul Holst | For identifying Glucagon-like peptides and leading the field with studies extending from cells to humans, culminating in the development of these peptides as therapeutic agents for treating diabetes and short bowel syndrome. [4] | Canada United States |
2019 | Ed Boyden, Karl Deisseroth, Peter Hegemann, Gero Miesenböck | For pioneering work in the field of optogenetics, a revolutionary technique that uses light and genetic modification to control the activity of cells in the brain. | United States |
2018 | Francis Collins, Paul Negulescu, Bonnie Ramsey, Lap-Chee Tsui, Michael J. Welsh | For identifying faulty gene behind devastating disease, development of precision-targeted therapies | United States China |
2017 | Arlene Sharpe, Harvard Medical School, Gordon J. Freeman, Dana Farber Cancer Institute, Lieping Chen, Yale University, James P. Allison, University of Texas M.D. Anderson Cancer Center, Tasuku Honjo, Kyoto University | For their collective contributions to the pre-clinical foundation and development of immune checkpoint blockade, a novel form of cancer therapy that has transformed the landscape of cancer treatment. [3] | United States Japan |
2016 | Rodolphe Barrangou, North Carolina State University, Philippe Horvath, DuPont, Jennifer Doudna, University of California, Berkeley, Emmanuelle Charpentier, Max Planck Institute for Infection Biology and Umeå University, Virginijus Šikšnys, Vilnius University Institute of Biotechnology | For their remarkable contributions to the understanding of the CRISPR bacterial defense system and the revolutionary discovery that it can be adapted for genome editing [5] | France United States |
2015 | Ruth Sonntag Nussenzweig and Victor Nussenzweig, NYU Langone Medical Center, Tu Youyou of the China Academy of Chinese Medical Sciences, Beijing | For their pioneering discoveries in chemistry and parasitology, and their personal commitment to translating these discoveries into effective chemotherapeutic and vaccine-based approaches to controlling malaria [6] | Brazil |
2014 | Oleh Hornykiewicz, Medical University of Vienna, Roger A. Nicoll, University of California, San Francisco, Solomon H. Snyder, Johns Hopkins School of Medicine | For seminal contributions to our understanding of neurotransmission and neurodegeneration. [7] [8] | Austria United States |
2013 | David Botstein, Princeton University, Ronald W. Davis, Stanford University School of Medicine, and David Hogness, Stanford University School of Medicine | For their seminal contributions to the concepts and methods of creating a genetic map in the human, and of positional cloning, leading to the identification of thousands of human disease genes and ushering in the era of human genetics. [7] [9] | United States |
2012 | Julian Adams, Infinity Pharmaceuticals, Kenneth C. Anderson, Dana–Farber Cancer Institute, Alfred L. Goldberg, Harvard Medical School, and Paul G. Richardson, Dana–Farber Cancer Institute [10] | For the discovery, preclinical and clinical development of bortezomib to FDA approval and front line therapy for the treatment of patients with multiple myeloma. [7] | United States |
2011 | Alain Carpentier, Hôpital Européen Georges-Pompidou, and Robert Langer, Massachusetts Institute of Technology | For their application of bioengineering principles to fundamental improvements in human health. [7] [11] | |
2009-2010 | Howard Green, Harvard Medical School | For development of methodologies for the expansion and differentiation of human keratinocyte stem cells for permanent skin restoration in victims of extensive burns. [7] [12] | United States |
2008 | Lloyd Aiello, Joslin Diabetes Center | For the discovery, characterization and implementation of laser panretinal photocoagulation, which is used to treat proliferative diabetic retinopathy [7] | United States |
2007 | Harald zur Hausen and Lutz Gissmann, German Cancer Research Center | For work leading to the development of a vaccine against human papillomavirus. [13] | Germany |
2006 | Dennis Slamon, UCLA; Robert Weinberg, MIT; Michael Shepard, Receptor BioLogix, Inc; and Axel Ullrich, Center for Molecular Medicine, | For their work in identifying HER-2/neu as an oncogene and development of the anti-HER-2/neu monoclonal antibody Herceptin for breast cancer therapy. [14] | United States Germany |
2005 | M. Judah Folkman, Harvard Medical School and Boston Children's Hospital | For discovering tumor angiogenesis, and for pioneering work in the development of antiangiogenic therapies for cancer. [7] | United States |
2004 | Susan Band Horwitz, Albert Einstein College of Medicine | For her seminal contributions to the understanding of how the antitumor agent Taxol kills cancer cells. | United States |
2003 | Sidney Pestka, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, David Goeddel, Tularik, Inc., and Charles Weissmann, Imperial College School of Medicine, London | For purification and characterization of interferon alpha; cloning of the human interferon alpha gene and mass production of recombinant interferon alpha for cancer treatment and treatment of hepatitis C. [7] | United Kingdom United States |
2002 | Alfred Sommer, Johns Hopkins University Bloomberg School of Public Health | For epidemiologic insight into the effects of Vitamin A deficiency, and the resulting reduction in childhood mortality worldwide. [7] | United States |
2001 | Eugene Braunwald, Harvard Medical School, and Barry Coller, Rockefeller University School of Medicine. | For work in cardiac physiology and pathophysiology, leading to the use of monoclonal antibodies to platelet surface antigens in antithrombotic therapy. [7] | United States |
2000 | David Baltimore, California Institute of Technology, Brian Druker, Oregon Health Sciences University, Nicholas Lydon, Amgen, Inc., Alex Matter, Novartis Pharma AG, and Owen Witte, University of California, Los Angeles. | For Development of Abl kinase inhibitors for use in the treatment of chronic myelogenous leukemia [7] | United States Switzerland |
1999 | Michael S. Brown and Joseph L. Goldstein, University of Texas Southwestern Medical School, Akira Endo (biochemist), Tokyo Noko University | For Development of HMG CoA reductase inhibitors. [7] | United States Japan |
1998 | K. Frank Austen, Harvard Medical School | For elucidating the role of leukotrienes in asthma. [7] | United States |
1997 | Robert C. Gallo, University of Maryland School of Medicine, and Luc Montagnier, Queens College, New York | For isolation of the Human Immunodeficiency Virus. [7] | United States France |
1996 | Leo Sachs, Weizmann Institute of Science, and Donald Metcalf, University of Melbourne | For discovery of blood cell growth factors. [7] | Israel Australia |
1995 | John A. Clements, University of California, San Francisco | For discovery of lung surfactant, and development of synthetic lung surfactant therapy for Infant Respiratory Distress Syndrome. [7] | United States |
1994 | J.R. Warren, Royal Perth Hospital, and Barry J. Marshall, University of Virginia | For linking gastric ulcers to the H. pylori bacterium. [7] | Australia |
1993 | Stuart H. Orkin, Harvard Medical School. | For genetic and molecular mechanisms of Βeta-Thalassemia and other blood disorders. [7] | United States |
1992 | Roscoe O. Brady, National Institutes of Health | For treatment for Gaucher's Disease. [7] | United States |
1991 | David W. Cushman and Miguel A. Ondetti, Bristol Myers-Squibb | For ACE inhibitor therapy for hypertension and heart failure. [7] | United States Argentina |
1990 | No prize awarded. [7] | ||
1989 | Yuet Wai Kan, University of California, San Francisco | For prenatal genetic screening for blood diseases. [7] | United States |
1988 | Louis Kunkel, Harvard Medical School | For discovery of the gene associated with a major form of muscular dystrophy. [7] | United States |
1987 | Kenneth Murray (biologist), University of Edinburgh | For development of a vaccine against Hepatitis B. [7] | Scotland |
The Warren Alpert Medical School is the medical school of Brown University, located in Providence, Rhode Island. Originally established in 1811, it was the third medical school to be founded in New England after only Harvard and Dartmouth. However, the original program was suspended in 1827, and the four-year medical program was re-established almost 150 years later in 1972, granting the first MD degrees in 1975.
Massachusetts General Hospital is a teaching hospital located in the West End neighborhood of Boston, Massachusetts. It is the original and largest clinical education and research facility of Harvard Medical School/Harvard University, and houses the world's largest hospital-based research program with an annual research budget of more than $1.2 billion in 2021. It is the third-oldest general hospital in the United States with a patient capacity of 999 beds. Along with Brigham and Women's Hospital, Mass General is a founding member of Mass General Brigham, formerly known as Partners HealthCare, the largest healthcare provider in Massachusetts.
Joseph Leonard Goldstein ForMemRS is an American biochemist. He received the Nobel Prize in Physiology or Medicine in 1985, along with fellow University of Texas Southwestern researcher, Michael Brown, for their studies regarding cholesterol. They discovered that human cells have low-density lipoprotein (LDL) receptors that remove cholesterol from the blood and that when LDL receptors are not present in sufficient numbers, individuals develop hypercholesterolemia and become at risk for cholesterol related diseases, notably coronary heart disease. Their studies led to the development of statin drugs.
Robert Samuel Langer Jr. FREng is an American biotechnologist, businessman, chemical engineer, chemist, and inventor. He is one of the nine Institute Professors at the Massachusetts Institute of Technology.
Dana–Farber Cancer Institute (DFCI) is a comprehensive cancer treatment and research center in Boston, Massachusetts. Dana-Farber is the founding member of the Dana-Farber/Harvard Cancer Center, Harvard's Comprehensive Cancer Center designated by the National Cancer Institute, and one of the 15 clinical affiliates and research institutes of Harvard Medical School.
Brian J. Druker, M.D. is a physician-scientist at Oregon Health & Science University (OHSU), in Portland, Oregon. He is the chief executive officer of OHSU's Knight Cancer Institute, JELD-WEN Chair of Leukemia Research, Associate Dean for Oncology in the OHSU School of Medicine, and professor of medicine.
Nicholas B. Lydon FRS is a British scientist and entrepreneur. In 2009, he was awarded the Lasker Clinical Award and in 2012 the Japan Prize for the development of Gleevec, also known as Imatinib, a selective BCR-ABL inhibitor for the treatment of chronic myeloid leukaemia (CML), which converted a fatal cancer into a manageable chronic condition.
Sidney Pestka was an American biochemist and geneticist. A recipient of the National Medal of Technology, he is sometimes referred to as the "father of interferon" for his groundbreaking work developing the interferons as treatments for major diseases such as hepatitis, multiple sclerosis, and cancer. Pestka was part of the team working on research involving the genetic code, protein synthesis and ribosome function that led to the 1968 Nobel Prize in Physiology or Medicine received by Marshall Warren Nirenberg.
George Quentin Daley is the Dean of the Faculty of Medicine, Caroline Shields Walker Professor of Medicine, and Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School. He was formerly the Robert A. Stranahan Professor of Pediatrics at Harvard Medical School, Director of the Stem Cell Transplantation Program at Boston Children's Hospital, and an investigator of the Howard Hughes Medical Institute, Associate Director of Children's Stem Cell Program, a member of the Executive Committee of the Harvard Stem Cell Institute. He is a past president of the International Society for Stem Cell Research (2007–2008).
Laurie Hollis Glimcher is an American physician-scientist and former President and CEO of Dana–Farber Cancer Institute. She was elected a member of the American Philosophical Society in 2019. Glimcher has been at the center of controversies related to animal rights activists, excessive corporate payments, and research misconduct. A 2021 investigation by the Boston Globe Spotlight team highlighted Glimcher’s activities on multiple corporate boards, including Bristol Myers Squibb, GlaxoSmithKline, and Analog Devices. After this investigation, Glimcher continued to receive compensation on for-profit boards, while doubling her salary to $4 million per year at Dana-Farber. In October 2024, Glimcher stepped down as President and CEO of Dana-Farber.
James Patrick Allison is an American immunologist and Nobel laureate who holds the position of professor and chair of immunology and executive director of immunotherapy platform at the MD Anderson Cancer Center in Houston, Texas. Allison is Regental Professor and Founding-Director of James P. Allison Institute at the MD Anderson Cancer Center.
Lynne Elizabeth Maquat is an American biochemist and molecular biologist whose research focuses on the cellular mechanisms of human disease. She is known for her work in describing the process of nonsense-mediated decay. She is an elected member of the American Academy of Arts and Sciences, the National Academy of Sciences and the National Academy of Medicine. She currently holds the J. Lowell Orbison Endowed Chair and is a professor of biochemistry and biophysics, pediatrics and oncology at the University of Rochester Medical Center.
Susan Band Horwitz is an American biochemist and professor at the Albert Einstein College of Medicine where she holds the Falkenstein chair in Cancer Research as well as co-chair of the department of Molecular Pharmacology.
Stuart Holland Orkin is an American physician, stem cell biologist and researcher in pediatric hematology-oncology. He is the David G. Nathan Distinguished Professor of Pediatrics at Harvard Medical School. Orkin's research has focused on the genetic basis of blood disorders. He is a member of the National Academy of Sciences and the Institute of Medicine, and an Investigator of the Howard Hughes Medical Institute.
Arlene Helen Sharpe is an American immunologist and Kolokotrones University Professor at Harvard University and Chair of the Department of Immunology at Harvard Medical School. In 2017, she received the Warren Alpert Foundation Prize with Gordon J. Freeman, Lieping Chen, James P. Allison and Tasuku Honjo for their collective contributions to the pre-clinical foundation and development of immune checkpoint blockade, a novel form of cancer therapy that has transformed the landscape of cancer treatment. She served as the hundredth president of the American Association of Immunologists from 2016 to 2017 and served as an AAI Council member from 2013 to 2016. She is the co-director of the Evergrande Center for Immunologic Diseases at Harvard Medical School and Brigham and Women's Hospital.
Joel Habener is a Professor of Medicine at Harvard Medical School.
George C. Tsokos is a Greek-American rheumatologist who serves as a Professor of Medicine at Harvard Medical School and the Chief of the Division of Rheumatology and Clinical Immunology at the Beth Israel Deaconess Medical Center, Boston. He is recognized as one of the foremost leaders of modern lupus research with landmark discoveries that have brought understanding of lupus to new levels, shedding light on how the disease develops and progresses over time.
Bonnie W. Ramsey is the Endowed Chair in Cystic Fibrosis at the University of Washington School of Medicine and the director of the Center for Clinical and Translational Research at Seattle Children's Research Institute. Her research focuses on treatments for cystic fibrosis.
Warren Alpert was an American entrepreneur and philanthropist. Born to poor immigrant parents, he served in U.S. military intelligence during World War II. His privately held businesses distributed gasoline, tobacco and food, and operated a chain of convenience stores and gas stations in the Northeastern United States. He gave away much of his fortune to support medical research at universities and hospitals, donating hundreds of millions of dollars.
Gordon J. Freeman is an American immunologist and oncologist at the Dana-Farber Cancer Institute and Harvard Medical School.